Natalizumab treatment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy
| Autor: | Totaro, R., Alessandra Lugaresi, Bellantonio, P., Danni, M., Costantino, G., Gasperini, C., Florio, C., Pucci, E., Maddestra, M., Spitaleri, D., Lus, G., Ardito, B., Farina, D., Rossi, M., Carmine, C. D. I., Altobelli, E., Maccarone, B., Casalena, A., Luca, G., Travaglini, D., Ioia, M. D. I., Tommaso, V. D. I., Fantozzi, R., Ruggieri, S., Provinciali, L., Riso, S., Mundi, C., Fuiani, A., Galgani, S., Maniscalco, G. T., Giuliani, G., Cartechini, E., Petretta, V., Fratta, M., Alfieri, G., Gatto, M., Carolei, A. |
|---|---|
| Přispěvatelé: | Totaro, R, Lugaresi, A, Bellantonio, P, Danni, M, Costantino, G, Gasperini, C, Florio, C, Pucci, E, Maddestra, M, Spitaleri, D, Lus, Giacomo, Ardito, B, Farina, D, Rossi, M, Di Carmine, C, Altobelli, E, Maccarone, B, Casalena, A, De Luca, G, Travaglini, D, Di Ioia, M, Di Tommaso, V, Fantozzi, R, Ruggieri, S, Provinciali, L, De Riso, S, Mundi, C, Fuiani, A, Galgani, S, Maniscalco, Gt, Giuliani, G, Cartechini, E, Petretta, V, Fratta, M, Alfieri, G, Gatto, M, Carolei, A., DIPARTIMENTO DI SCIENZE BIOMEDICHE E NEUROMOTORIE |
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
Adult
Male medicine.medical_specialty Time Factors Antibodies Monoclonal Humanized Disability Evaluation Disease Progression Disease-Free Survival Female Humans Immunosuppressive Agents Italy Kaplan-Meier Estimate Magnetic Resonance Imaging Middle Aged Multiple Sclerosis Relapsing-Remitting Natalizumab Product Surveillance Postmarketing Treatment Outcome Immunology Relapsing-Remitting multiple sclerosis Antibodies Internal medicine Monoclonal medicine Immunology and Allergy Humanized Pharmacology Expanded Disability Status Scale medicine.diagnostic_test treatment business.industry Multiple sclerosis Disease progression Magnetic resonance imaging multi center medicine.disease Product Surveillance Postmarketing Clinical Practice Physical therapy Observational study multiple sclerosis treatment natalizumab multi center Italy business medicine.drug |
| Zdroj: | Scopus-Elsevier Sapienza Università di Roma-IRIS |
| Popis: | none 39 no Articolo con dati scientifici originali pubblicato nella sezione "Editorial" della rivista We evaluated efficacy of natalizumab in relapsing-remitting multiple sclerosis patients in a clinical practice setting. We report data on the first consecutive 343 patients receiving natalizumab in 12 multiple sclerosis (MS) Italian centers enrolled between April 2007 and November 2010. The main efficacy endpoints were the proportion of patients free from relapses, disease progression, combined clinical activity, defined as presence of relapse or disease progression, from MRI activity, and from any disease activity defined as the absence of any single or combined activity. At the end of follow-up, the cumulative proportion of patients free from relapses was 68%; the proportion of patients free from Expanded Disability Status Scale (EDSS) progression was 93%; the proportion of patients free from combined clinical activity was 65%; the proportion of patients free from MRI activity was 77%; and the proportion of patients free from any disease activity was 53%. Natalizumab was effective in reducing clinical and neuroradiological disease activity. Its effectiveness in clinical practice is higher than that reported in pivotal trials and was maintained over time. none Totaro R; Lugaresi A; Bellantonio P; Danni M; Costantino G; Gasperini C; Florio C; Pucci E; Maddestra M; Spitaleri D; Lus G; Ardito B; Farina D; Rossi M; Di Carmine C; Altobelli E; Maccarone B; Casalena A; De Luca G; Travaglini D; Di Ioia M; Di Tommaso V; Fantozzi R; Ruggieri S; Provinciali L; De Riso S; Mundi C; Fuiani A; Galgani S; Ruggieri S; Maniscalco GT; Giuliani G; Cartechini E; Petretta V; Fratta M; Alfieri G; Gatto M; Carolei A; Natalizumab Long-Term Treatment Study group Totaro R; Lugaresi A; Bellantonio P; Danni M; Costantino G; Gasperini C; Florio C; Pucci E; Maddestra M; Spitaleri D; Lus G; Ardito B; Farina D; Rossi M; Di Carmine C; Altobelli E; Maccarone B; Casalena A; De Luca G; Travaglini D; Di Ioia M; Di Tommaso V; Fantozzi R; Ruggieri S; Provinciali L; De Riso S; Mundi C; Fuiani A; Galgani S; Ruggieri S; Maniscalco GT; Giuliani G; Cartechini E; Petretta V; Fratta M; Alfieri G; Gatto M; Carolei A; Natalizumab Long-Term Treatment Study group |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|